FDA Grants Breakthrough Therapy Designation to SPK-9001

Spark Therapeutics and Pfizer have earned breakthrough therapy designation for their hemophilia b candidate SPK-9001.

SPK-9001 is being considered to eliminate blood infusions for single-use gene therapy.